Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in the urine of children with pyelonephritis;Metaloproteinazy 2 i 9 oraz ich tkankowe inhibitory 1 i 2 w moczu dzieci chorých na odmiedniczkowe zapalenie nerek

Polski Merkuriusz Lekarski

Volumn 27, Issue 157, 2009, Pages 10-13

  Tenderenda, E ^a   Zoch Zwierz, W ^a   Wasilewska, A ^a   Porowski, T ^a   Taranta Janusz, K ^a   Kolodziejczyk, Z ^a   Michaluk Skutnik, J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

MMP 2; MMP 9; Pyelonephritis; TIMP 1; TIMP 2

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADOLESCENT; ARTICLE; CHILD; FEMALE; HUMAN; INFANT; MALE; PRESCHOOL CHILD; PYELONEPHRITIS; URINE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PYELONEPHRITIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 68949211093     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bauvois B., Mothu N., Nguyen J. i wsp.: Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. Nephrol. Dia.l Transplant., 2007, 22, 1115-1122.
2. Blobe G.C., Schiemann W.P., Lodish H.F.: Role of transforming growth factor beta in human disease. N. Engl. J. Med., 2000, 342, 350-1358.
3. BodeW, Maskos K.: Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol. Chem., 2003, 384, 863-872.
4. Han S.Y., Jee Y.H., Han K.H: i wsp.: An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol. Dial. Transplant, 2006, 21, 2406-2416.
5. Chromek M., Tullus K., Hertting O. i wsp.: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediat. Res., 2003, 53, 698-705.
6. Chromek M., Tullus K., Lundahl J.i wsp.: Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect. Immun., 2004, 72, 82-88.
7. Doganis ., Siafas K., Mavrikou M. i wsp.: Does early treatment of urinary tract infection prevent renal damage? Pediatrics, 2007, 120, 922-928.
8. Eddy A.A., Kim H., López-Guisa J. i wsp: Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective.,Kidney Int., 2000, 58, 618-628.
9. Garin E.H., Olavarria R, Garcia Nieto V.i wsp.: Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis añer acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics, 2006, 117, 626-632.
10. Hertting O., Khalil A., Jaremko G.i wsp.: Enhanced chemokine response in experimental acute Escherichia coli pyelonephritis in IL-1 beta-deficient mice. Clin. Exp. Immunol., 2003, 131, 225-233.
11. Hörstrup J.H., Gehrmann M., Schneider B.i wsp.: Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol. Dial. Transplant., 2002, 17, 1005-1013.
12. Ichino M., Mori T., Kusaka M. i wsp.: Global gene expression profiling of renal scarring in a rat model of pyelonephritis. Pediatr. Nephrol., 2008, 23, 1059-1071.
13. Johnson TS., Haylor J.L., Thomas G.L. i wsp.: Matrix metalloproteinases and their inhibitions in experimental renal scarring. Exp. Nephrol., 2002, 10, 182-195.
14. Kuroda T., Yoshida Y., Kamiie J. i wsp.: Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats. Clin. Exp. Nephrol., 2004, 8, 206-215.
15. Lin K.Y., Chiu N.T., Chen M.J. i wsp.: Acute pyelonephritis and sequelae of renal scar in pediatric first febrile urinary tract infection. Pediatr. Nephrol., 2003, 18, 362-365.
16. Liu Y. : Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int., 2006, 69, 213-217.
17. Nagase H., Woessner J.F. i wsp: Matrix metalloproteinases. J. Biol. Chem., 1999, 274, 21491-21494.
18. Nee L., Tuite N., Ryan M.P. i wsp.: TNF-alpha and IL-1 beta-mediated regulation of MMP-9 and TIMP-1 in human glomerular mesangial cells. Nephron Exp. Nephrol., 2007, 107, 73-86.
19. Orellana P., Baquedano P., Rangarajan V. I wsp.: Relationship between acute pyelonephritis, renal scarring, and vesicoureteral reflux. Results of a coordinated research project. Pediatr. Nephrol., 2004, 19, 1122-1126.
20. Page-McCaw A., Ewald A.J., Werb Z.: Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol., 2007, 8, 221-233.
21. Ravanti L., Kähäri V.M.: Matrix metalloproteinases in wound repair (review). Int. J. Mol. Med., 2000, 6, 391-407.
22. Sabasiṅska A., Zoch-Zwierz W., Wasilewska A. i wsp.: Laminin and transfonming growth factor beta-1 in children with vesicoureteric reflux. Pediatr. Nephrol., 2008, 23, 769-774.
23. Sabasiňska A., Zoch-Zwierz W., Wasilewska A. i wsp.: Serum and urine fibronectin levels in children with vesicoureteral reflux. Pediatr. Nephrol., 2007, 22, 1173-1179.
24. 24. Sanders J.S., Huitema M.G., Hanemaaijer R. i wsp.: Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Am. J. Physiol. Renal Physiol., 2007, 29, F1927-1934.
25. Thrailkill K.M., Bunn R.C., Moreau CS. I wsp.: Matrix metalloproteinase2 dysregulation in type 1 diabetes. Diabetes Care., 2007, 30, 2321-2326.
26. Yang M., Huang H., Li J.: Connective tissue growth factor increases matrix etalloproteinase-2 and suppresses tissue inhibitor of matrix metalloproteinase-2 production by cultured renal interstitial fibroblasts. Wound Repair. Regen., 2007, 15, 817-824.